Clinical Research Doctors Pharmaceuticals Treatment 
Drug Discovery World
DECEMBER 18, 2023
With a staggering 450,000 clinical trials 3 registered globally to address these pressing health issues, and an average failure rate of 90% 4 , the call to accelerate and revolutionise clinical research is paramount. They mark a significant shift in clinical research, utilising technology to capture real-time patient data.
Drug Discovery World
JUNE 20, 2024
Now, you might wonder: how exactly can these advanced artificial intelligence models propel clinical research forward? In the context of clinical trials, these models can help us add context to insights. Conventional AI models allow us to extract insights from the clinical data but they do lack context.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
H1 Blog
MAY 4, 2023
Insights for Thought Leading Stakeholder Engagement to Decrease Medication Non-Adherence Pharmaceutical companies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drug development, and medical education.
Drug Discovery World
APRIL 14, 2023
She is also a Professor of Pathology at the Johns Hopkins University School of Medicine, Co-director of the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care, and Deputy Director of the Johns Hopkins Institute for Clinical and Translational Research.
The Pharma Data
JANUARY 14, 2021
Dr. Dickstein enjoyed 30 years in the pharmaceutical field before retiring in 1998 as the vice president of clinical research for Transcend Therapeutics, Inc. Dickstein remains a pharmaceutical consultant in his hometown of Cohasset, Massachusetts, since 1999.
The Pharma Data
DECEMBER 15, 2020
(hereinafter referred to as: CHIPSCREEN BIOSCIENCES) and ZHEJIANG HISUN PHARMACEUTICAL CO., hereinafter referred to as: HISUN PHARMACEUTICAL) announced that they have reached a strategic cooperation. This cooperation intends to quickly provide to Chinese patients with this innovative diabetes treatment mechanism.
The Pharma Data
SEPTEMBER 1, 2021
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults.
Expert insights. Personalized for you.
147 
Let's personalize your content